Thought-provoking oped highlighting the underbelly of buzzwords in healthcare today. The shift from volume to value that we’ve seen unfold over the past 3-5 years has moved front and center in many conversations, yet remains elusive insofar as its definition and implementation. This article rightly calls out that value is ultimately in the eye of the beholder, and yet there’s no disputing that doing what’s right for the patient trumps all.
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Another PARP-inhibitor in this setting with reasonable toxicity profile and flexibility of efficacy for patients with mutated or non-mutated BRCA status. More options of therapy may decrease cost of treatment in a competitive market.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
DD-LPS is certainly a disease-process with unmet therapeutic needs. Selinexor versus BSC showed significant PFS improvement. Very interested in validation studies of CALB1 expression and potential combinations with Selinexor.
Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer
This is an excellent article demonstrating the stark changes in mortality pre- and post-Medicaid expansion. Further advocacy efforts are needed to enhance access to care, minimize negative social determinants of health. Maintaining the population at risk healthier, with access to guidelines-driven care should not be a matter of much debate, but an action point for our legislators.
Very robust improvement of response rate, progression-free survival and decreased risk of death with trastuzumab deruxtecan versus trastuzumab emtansine. Early detection, knowledge about management and pre-treatment risk assessment of pulmonary toxicities are of paramount importance.
Practice-changing study for this specific patient population (see inclusion criteria) with approximately 30% risk reduction of death with excellent tolerability of treatment arm of this study.
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
Lots of progress to be accomplished here. Increased standardization of care, quality metrics based on guideline-adherence and best practices remain critical to progress.
Another landmark study supporting the use CDK4/6 drugs along with endocrine therapy in the breast cancer metastatic setting. Missed opportunities insofar as adding CDK 4/6 drugs to endocrine blockade are a concern, since the OS survival difference is significant.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Important guideline update in a very common clinical scenario. Most practitioners prescribe antiresorptive therapy to prevent osteoporosis/osteopenia in the setting of aromatase-therapy inhibitors. Guidelines recommend consideration of bisphosphonate therapy irrespective of endocrine-tumor status.
Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
Another trial corroborating the activity of poziotinib in this setting.